Codeine

Codeine

SCHEMBL8218174

COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4C(C2)N(C)CC[C@@]341

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRD1OPRK1OPRM1

The experimentally established mechanism targets of Codeine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
OPRD1 known ✓ P41143 9/20 1.00
OPRM1 known ✓ P35372 7/20 1.00
OPRK1 known ✓ P41145 5/20 1.00
MRGPRX2 Q96LB1 4/20 1.00
ADRB1 P08588 1/20 1.00
PDE4D Q08499 1/20 1.00
PDE3A Q14432 1/20 1.00
SLC22A1 O15245 1/20 0.76
ADRA2A P08913 1/20 0.76
ARRB1 P49407 1/20 0.76
SLC18A3 Q16572 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Codeine SCHEMBL1276342 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL10329428 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL16922140 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL13696342 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL3257 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL1560699 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL12638890 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL14371354 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL21077535 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1MRGPRX2ADRB1
Codeine SCHEMBL16922135 1.00 OPRD1 (1.00) OPRD1OPRM1OPRK1MRGPRX2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10791691-B2 Papaver somniferum with high concentration of codeine TASMANIAN ALKALOIDS PTY. LTD. (AU) 2020-10-06 US disclosed
US-10760090-B2 Papaver somniferum strain with high concentration of thebaine TASMANIAN ALKALOIDS PTY. LTD. (AU) 2020-09-01 US disclosed
US-20190185869-A1 P. SOMNIFERUM PLANTS FOR THE PRODUCTION OF CODEINE TASMANIAN ALKALOIDS PTY LTD (AU) 2019-06-20 US disclosed
WO-2018039749-A1 P. SOMNIFERUM PLANTS FOR THE PRODUCTION OF CODEINE TASMANIAN ALKALOIDS PTY LTD (AU) 2018-03-08 WO disclosed
US-9909137-B2 Papaver somniferum strain with high concentration of thebaine TASMANIAN ALKALOIDS PTY. LTD. (AU) 2018-03-06 US disclosed
US-20170280647-A1 PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE TASMANIAN ALKALOIDS PTY LTD (AU) 2017-10-05 US disclosed
US-9648815-B2 Papaver somniferum with high concentration of codeine TASMANIAN ALKALOIDS PTY. LTD. (AU) 2017-05-16 US disclosed
US-20160317662-A1 STABLE ORAL PHARMACEUTICAL COMPOSITION HYPERMARCAS S.A. (BR) 2016-11-03 US disclosed
WO-2014172482-A1 COMPOUNDS FOR TREATMENT OF PAIN VOLKMANN ROBERT ALFRED (US) 2014-10-23 WO disclosed
US-8541647-B2 Papaver somniferum with high concentration of codeine Tasmania Alkaloids Pty, Ltd. (AU) 2013-09-24 US disclosed
US-8541647-B2 Papaver somniferum with high concentration of codeine Tasmania Alkaloids Pty, Ltd. (AU) 2013-09-24 US disclosed
US-20130205452-A1 PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE TASMANIA ALKALOIDS PTY. LTD. (AU) 2013-08-08 US disclosed
US-8067213-B2 use of a mutagenized Papaver somniferum poppy plant to produce thebaine and oripavine in higher yield; morphine, codeine Tasmanian Alkaloids Pty., Ltd. (AU) 2011-11-29 US disclosed
US-7928234-B2 Conversion of thebaine to morphine derivatives BROCK UNIVERSITY (CA) 2011-04-19 US disclosed
US-20100234600-A1 PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE CERBERUS BUSINESS FINANCE, LLC, AS COLLATERAL AGENT 2010-09-16 US disclosed
US-20090005563-A1 CONVERSION OF THEBAINE TO MORPHINE DERIVATIVES BROCK UNIVERSITY 2009-01-01 US disclosed
WO-2008010222-A2 CONJUGATES COMPRISING A GABA- OR GLYCINE COMPOUND, PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS THEREOF AND THEIR USE IN TREATING CNS DISORDERS RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10760090-B2 Papaver somniferum strain with high concentration of thebaine OPRM1, POF1B, OPRK1 OPRD1 16/4885OPRM1 1/4885OPRK1 3/4885
US-10791691-B2 Papaver somniferum with high concentration of codeine OPRM1, OPRK1, CPNE4 OPRD1 12/4885OPRM1 1/4885OPRK1 2/4885
US-20160317662-A1 STABLE ORAL PHARMACEUTICAL COMPOSITION OPRD1, OPRK1, OPRM1 OPRD1 1/4885OPRM1 3/4885OPRK1 2/4885
US-20090005563-A1 CONVERSION OF THEBAINE TO MORPHINE DERIVATIVES OPRK1, OPRM1, OPRD1 OPRD1 3/4885OPRM1 2/4885OPRK1 1/4885
US-20170280647-A1 PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE OPRM1, OPRK1, CPNE4 OPRD1 12/4885OPRM1 1/4885OPRK1 2/4885
US-20100234600-A1 PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE OPRM1, OPRK1, POF1B OPRD1 5/4885OPRM1 1/4885OPRK1 2/4885
US-20130205452-A1 PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE OPRM1, OPRK1, POF1B OPRD1 5/4885OPRM1 1/4885OPRK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.